Association of obesity-related metabolic disruptions with cancer risk and outcome

Journal of Clinical Oncology

Volumn 34, Issue 35, 2016, Pages 4249-4255

  Lohmann, Ana Elisa ^a   Goodwin, Pamela J ^a   Chlebowski, Rowan T ^d   Pan, Kathy ^d   Stambolic, Vuk ^b,c   Dowling, Ryan J O ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; SEX HORMONE;

BREAST CANCER; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); METABOLIC DISORDER; OBESITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADIPOSE TISSUE; COMPLICATION; ENERGY METABOLISM; INFLAMMATION; METABOLISM; NEOPLASM; RISK FACTOR;

ADIPOKINES; ADIPOSE TISSUE; ENERGY METABOLISM; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 85002547577     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.6187     Document Type: Review

References (84)

1. NCD Risk Factor Collaboration (NCD-RisC): Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19$2 million participants. Lancet 387:1377-1396, 2016
2. Secord AA, Hasselblad V, Von Gruenigen VE, et al: Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol 140:184-190, 2016
3. Kocarnik JM, Chan AT, Slattery ML, et al: Relationship of prediagnostic body mass index with survival after colorectal cancer: Stage-specific associations. Int J Cancer 139:1065-1072, 2016
4. Chan D S M, Vieira AR, Aune D, et al: Body mass index and survival in women with breast cancersystematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901-1914, 2014
5. Goodwin PJ, Stambolic V: Impact of the obesity epidemic on cancer. Annu Rev Med 66:281-296, 2015
6. Emerging Risk Factors Collaboration: Seshasai SR, Kaptoge S, et al: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829-841, 2011
7. Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325-337, 2011
8. Macheda ML, Rogers S, Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662, 2005
9. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-674, 2011
10. Pisani P: Hyper-insulinaemia and cancer, metaanalyses of epidemiological studies. Arch Physiol Biochem 114:63-70, 2008
11. Dankner R, Shanik MH, Keinan-Boker L, et al: Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: The Israel GOH 29-year follow-up study. Diabetes Care 35:1538-1543, 2012
12. Lawrence MC, McKern NM, Ward CW: Insulin receptor structure and its implications for the IGF-1 receptor. Curr Opin Struct Biol 17:699-705, 2007
13. Seino S, Seino M, Nishi S, et al: Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 86:114-118, 1989
14. Moller DE, Yokota A, Caro JF, et al: Tissuespecific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3:1263-1269, 1989
15. Denley A, Wallace JC, Cosgrove LJ, et al: The insulin receptor isoform exon 11-(IR-A) in cancer and other diseases: A review. Horm Metab Res 35:778-785, 2003
16. Belfiore A, Malaguarnera R: Insulin receptor and cancer. Endocr Relat Cancer 18:R125-R147, 2011
17. Taniguchi CM, Emanuelli B, Kahn CR: Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 7:85-96, 2006
18. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30:35-42, 2005
19. Skolnik EY, Batzer A, Li N, et al: The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260:1953-1955, 1993
20. Vigneri R, Goldfine ID, Frittitta L: Insulin, insulin receptors, and cancer. J Endocrinol Invest [epub ahead of print on July 1, 2016] doi:10.1007/s40618-016-0508-7
21. Belfiore A, Frasca F, Pandini G, et al: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623, 2009
22. Dowling RJ, Niraula S, Chang MC, et al: Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res 17:32, 2015
23. Mulligan AM, O'Malley FP, Ennis M, et al: Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39-47, 2007
24. Law JH, Habibi G, Hu K, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238-10246, 2008
25. Goodwin PJ, Ennis M, Pritchard KI, et al: Insulinand obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J Clin Oncol 30:164-171, 2012
26. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42-51, 2002
27. You J, Liu WY, Zhu GQ, et al: Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget 6:19880-19890, 2015
28. Macleod LC, Chery LJ, Hu EY, et al: Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort. Prostate Cancer Prostatic Dis 18:190-195, 2015
29. Duggan C, IrwinML, Xiao L, et al: Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29:32-39, 2011
30. Oh SW, Park CY, Lee ES, et al: Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 13:R34, 2011
31. Goodwin PJ, Ennis M, Fantus IG, et al: Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23:6037-6042, 2005
32. Artac M, Bozcuk H, Kiyici A, et al: Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Breast Cancer 20:174-180, 2013
33. Ferroni P, Palmirotta R, Spila A, et al: Prognostic significance of adiponectin levels in nonmetastatic colorectal cancer. Anticancer Res 27(1B):483-489, 2007
34. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al: Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 60:1530-1538, 2011
35. Healy LA, Howard JM, Ryan AM, et al: Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal Dis 14:157-165, 2012
36. Li H, Stampfer MJ, Mucci L, et al: A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56:34-43, 2010
37. Stevens VL, Jacobs EJ, Sun J, et al: No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 23:890-892, 2014
38. Burton A, Martin RM, Holly J, et al: Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control 24:323-334, 2013
39. Bhandari R, Kelley GA, Hartley TA, et al: Metabolic syndrome is associated with increased breast cancer risk: A systematic review with metaanalysis. Int J Breast Cancer 2014:189384, 2014
40. Bjørge T, Lukanova A, Jonsson H, et al: Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 19:1737-1745, 2010
41. Flood A, Mai V, Pfeiffer R, et al: Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology 133:1423-1429, 2007
42. 41a. Taniguchi L, Higurashi T, Uchiyama T, et al: Metabolic factors accelerate colorectal adenoma recurrence. BMC Gastroenterol 14:187, 2014
43. Wolpin BM, Meyerhardt JA, Chan AT, et al: Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185, 2009
44. Abbruzzese C, Diodoro MG, Sperduti I, et al: Detection of phosphorylated insulin receptor in colorectal adenoma and adenocarcinoma: Implications for prognosis and clinical outcome. J Cell Physiol 230:562-567, 2015
45. Ma J, Li H, Giovannucci E, et al: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 9:1039-1047, 2008
46. Wright JL, Plymate SR, Porter MP, et al: Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis 16:204-208, 2013
47. Lehrer S, Diamond EJ, Stagger S, et al: Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50:1-3, 2002
48. Lee CH, Woo YC, Wang Y, et al: Obesity, adipokines and cancer: An update. Clin Endocrinol (Oxf) 83:147-156, 2015
49. Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, et al: Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) 5:65, 2014
50. Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: A review of current evidence. Endocr Rev 33:547-594, 2012
51. Raucci R, Rusolo F, Sharma A, et al: Functional and structural features of adipokine family. Cytokine 61:1-14, 2013
52. Alshaker H, Sacco K, Alfraidi A, et al: Leptin signalling, obesity and prostate cancer: Molecular and clinical perspective on the old dilemma. Oncotarget 6:35556-35563, 2015
53. Macis D, Guerrieri-Gonzaga A, Gandini S: Circulating adiponectin and breast cancer risk: A systematic review and meta-analysis. Int J Epidemiol 43:1226-1236, 2014
54. Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al: Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: A prospective study. Cancer Epidemiol Biomarkers Prev 22:1319-1324, 2013
55. Cleary MP, Ray A, Rogozina OP, et al: Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 1:329-357, 2009
56. Joshi RK, Lee SA: Obesity related adipokines and colorectal cancer: A review and meta-analysis. Asian Pac J Cancer Prev 15:397-405, 2014
57. Fowke JH, Motley S, Dai Q, et al: Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer-evidence of effect modification by prostate size. Cancer Lett 328:345-352, 2013
58. Brown SB, Hankinson SE: Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 99(Pt A):8-10, 2015
59. Kaaks R, Berrino F, Key T, et al: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97:755-765, 2005
60. Key TJ, Appleby PN, Reeves GK, et al; Endogenous Hormones and Breast Cancer Collaborative Group: Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids 99(Pt A):49-55, 2015
61. Lønning PE, Helle SI, Johannessen DC, et al: Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat 39:335-341, 1996
62. Holmberg L, Nordén T, Lindgren A, et al: Preoperative oestradiol levels - relation to survival in breast cancer. Eur J Surg Oncol 27:152-156, 2001
63. Micheli A, Meneghini E, Secreto G, et al: Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 25:2685-2690, 2007
64. Kim JY, Han W, Moon HG, et al: Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer 13:503, 2013
65. Benn M, Voss SS, Holmegard HN, et al: Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women. Arterioscler Thromb Vasc Biol 35:471-477, 2015
66. Duggan C, Stanczyk F, Campbell K, et al: Associations of sex steroid hormones with mortality in women with breast cancer. Breast Cancer Res Treat 155:559-567, 2016
67. Brinton LA, Trabert B, Anderson GL, et al: Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 25:1081-1089, 2016
68. Park J, Cho SY, Jeong SH, et al: Low testosterone level is an independent risk factor for highgrade prostate cancer detection at biopsy. BJU Int 118:230-235, 2016
69. Garćýa-Cruz E, Carrión Puig A, Garćýa-Larrosa A, et al: Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy. Scand J Urol 47:282-289, 2013
70. Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625, 2009
71. Bowker SL, Majumdar SR, Veugelers P, et al: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258, 2006
72. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005
73. Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812, 2007
74. Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915, 2009
75. Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273, 2006
76. Niraula S, Dowling RJ, Ennis M, et al: Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821-830, 2012
77. Hadad S, Iwamoto T, Jordan L, et al: Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794, 2011
78. Joshua AM, Zannella VE, Downes MR, et al: A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17:252-258, 2014
79. Miranda VC, Braghiroli MI, Faria LD, et al: Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer. Clin Colorectal Cancer pii: S1533-0028 (16) 30059-7, 2016
80. Kordes S, Pollak MN, Zwinderman AH, et al: Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16:839-847, 2015
81. Goodwin PJ, Parulekar WR, Gelmon KA, et al: Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. J Natl Cancer Inst 107:djv006, 2015
82. ClinicalTrials.gov: Paclitaxel and carboplatin with or without metformin hydrochloride in treating patients with stage III, IV, or recurrent endometrial cancer. https://clinicaltrials.gov/ct2/show/NCT02065687? term=GOG+metformin&rank=1
83. ClinicalTrials.gov: The Metformin Active Surveillance Trial (MAST) study. https://clinicaltrials.gov/ct2/show/NCT01864096?term=low+risk+prostate+ cancer+AND+metformin&rank=1
84. Chlebowski RT, Reeves MM: Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol 34:4238-4248, 2016